Illumina TruSight Oncology 500 HRD Assay
Illumina has launched the TruSight Oncology 500 HRD assay, a next-generation sequencing-based clinical assay for homologous recombination deficiency status. The test, codeveloped with Merck and based on validated HRD technology from Myriad Genetics, analyzes more than 500 genes, including those relevant to HRD status. HRD signatures occur when cells are unable to effectively repair double-strand breaks in DNA. Illumina expects to ship the kit in August, however, the test will not be available in the US and Japan.